Large artery stiffness and hypertension after antiangiogenic drugs: Influence on cancer progression

Journal of Hypertension

Volumn 33, Issue 6, 2015, Pages 1310-1317

  Alivon, Maureen ^a,b,c   Giroux, Julie ^a,b,c   Briet, Marie ^a,b   Goldwasser, François ^a,b   Laurent, Stéphane ^a,b   Boutouyrie, Pierre ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

^c Maureen Alivon and Julie Giroux Contributed Equally to the Writing of This Article   (France)

Author keywords

antiangiogenic drugs; aorta; arteries; blood pressure; hypertension; stiffness

Indexed keywords

SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR;

ADULT; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE AGED; MONOTHERAPY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; SYSTOLIC BLOOD PRESSURE; THYROID CARCINOMA; TREATMENT RESPONSE; AGED; AORTA; ARTERY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CHEMICALLY INDUCED; DISEASE COURSE; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ADULT; AGED; ANGIOGENESIS INHIBITORS; AORTA; ARTERIES; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84929484423     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000550     Document Type: Article

References (51)

1. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008; 34:37-48.
2. Eichholz A, Merchant S, Gaya AM. Antiangiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010; 3:69-82.
3. Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, et al. FDA approval summary: sunitinib for the treatment of progressive well differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 2012; 17:1108-1113.
4. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28:2280-2285.
5. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011-2019.
6. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9:117-123.
7. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011; 16:1325-1332.
8. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48:9-17.
9. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358:95-97.
10. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15:6250-6257.
11. Halimi JM, Azizi M, Bobrie G, Bouche O, Deray G, des Guetz G, et al. Vascular and renal effects of antiangiogenic therapy. Nephrol Ther 2008; 4:602-615.
12. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19:927-934.
13. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56:1131-1136.
14. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7:193-201.
15. Lattimer SA, Sima AA, Greene DA. In vitro correction of impaired Na-K-ATPase in diabetic nerve by protein kinase C agonists. Am J Physiol 1989; 256 (2 Pt 1):E264-E269.
16. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56:675-681.
17. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59:151-157.
18. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013; 18:273-280.
19. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 2012; 308:875-881.
20. Stefanadis CI, Karayannacos PE, Boudoulas HK, Stratos CG, Vlachopoulos CV, Dontas IA, Toutouzas PK. Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. Cardiovasc Res 1993; 27:951-956.
21. Stefanadis C, Vlachopoulos C, Karayannacos P, Boudoulas H, Stratos C, Filippides T, et al. Effect of vasa vasorum flow on structure and function of the aorta in experimental animals. Circulation 1995; 91:2669-2678.
22. Angouras D, Sokolis DP, Dosios T, Kostomitsopoulos N, Boudoulas H, Skalkeas G, Karayannacos PE. Effect of impaired vasa vasorum flow on the structure and mechanics of the thoracic aorta: implications for the pathogenesis of aortic dissection. Eur J Cardiothorac Surg 2000; 17:468-473.
23. Osada H, Kyogoku M, Ishidou M, Morishima M, Nakajima H. Aortic dissection in the outer third of the media: what is the role of the vasa vasorum in the triggering process? Eur J Cardiothorac Surg 2013; 43:e82-e88.
24. Bry M, Kivela R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010; 122:1725-1733.
25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
26. Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs 2012; 30:702-707.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
28. Boutouyrie P, Germain DP, Fiessinger JN, Laloux B, Perdu J, Laurent S. Increased carotid wall stress in vascular Ehlers-Danlos syndrome. Circulation 2004; 109:1530-1535.
29. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al., European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
30. Collaboration RVfAS. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31:2338-2350.
31. Meinders JM, Hoeks AP. Simultaneous assessment of diameter and pressure waveforms in the carotid artery. Ultrasound Med Biol 2004; 30:147-154.
32. Paini A, Boutouyrie P, Calvet D, Tropeano AI, Laloux B, Laurent S. Carotid and aortic stiffness: determinants of discrepancies. Hypertension 2006; 47:371-376.
33. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, Laurent S, Boutouyrie P. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a metaanalysis of individual data in 294 patients. J Hypertens 2011; 29:1034-1042.
34. Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J 2013; 34:2368-2380.
35. Berry L. Better long-term support needed to cut cancer deaths. Nurs Older People 2012; 24:7.
36. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368:351-364.
37. Boutouyrie P, Achouba A, Trunet P, Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010; 55:1314-1322.
38. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005; 45:1050-1055.
39. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009; 116:1755-1761.
40. Louis H, Kakou A, Regnault V, Labat C, Bressenot A, Gao-Li J, et al. Role of alpha1beta1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice. Am J Physiol Heart Circ Physiol 2007; 293:H2597-H2604.
41. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014; 63:520-526.
42. Gossl M, Malyar NM, Rosol M, Beighley PE, Ritman EL. Impact of coronary vasa vasorum functional structure on coronary vessel wall perfusion distribution. Am J Physiol Heart Circ Physiol 2003; 285:H2019-H2026.
43. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 2013; 22:399-411.
44. Alghatrif M, Strait JB, Morrell CH, Canepa M, Wright J, Elango P, et al. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension 2013; 62:934-941.
45. Bartsch P, Gibbs JS. Effect of altitude on the heart and the lungs. Circulation 2007; 116:2191-2202.
46. Koller A, Toth P. Contribution of flow-dependent vasomotor mechanisms to the autoregulation of cerebral blood flow. J Vasc Res 2012; 49:375-389.
47. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18 (1 Pt 2):3S-10S.
48. Sharman JE, Davies JE, Jenkins C, Marwick TH. Augmentation index, left ventricular contractility, and wave reflection. Hypertension 2009; 54:1099-1105.
49. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension 2009; 54:388-392.
50. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31:2205-2218.
51. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10:417-427.